FDA Accepts NDA for DHE STS101 Nasal Powder Product for Acute Migraine
The FDA accepted Satsuma Pharmaceuticals 505(b)(2) New Drug Application (NDA) for its investigational new dihydroergotamine (DHE) nasal powder product, STS101, […]
The FDA accepted Satsuma Pharmaceuticals 505(b)(2) New Drug Application (NDA) for its investigational new dihydroergotamine (DHE) nasal powder product, STS101, […]